Matsumoto Yoshiko, Saito Motonobu, Saito Katsuharu, Kanke Yasuyuki, Watanabe Yohei, Onozawa Hisashi, Hayase Suguru, Sakamoto Wataru, Ishigame Teruhide, Momma Tomoyuki, Kumamoto Kensuke, Ohki Shinji, Takenoshita Seiichi
Department of Organ Regulatory Surgery, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.
Oncol Lett. 2018 Feb;15(2):2188-2194. doi: 10.3892/ol.2017.7555. Epub 2017 Dec 8.
Kinesin family member 4A (KIF4A) is a member of the kinesin 4 subfamily of kinesin-related proteins and serves an important role in cell division. The expression levels of KIF4A have been investigated in numerous types of cancer, including cervical, lung, oral, and breast cancer, and are established to be associated with poor patient prognosis. However, the role of KIF4A, as well as its expression in colorectal cancer (CRC), remains to be elucidated. Therefore, the current study investigated KIF4A expression levels in patients with CRC and demonstrated that its levels were increased in tumor tissues compared with non-tumor tissues. To investigate the functional role of KIF4A, KIF4A was knocked down in CRC cells and cell viability was evaluated. CRC cells with KIF4A knockdown exhibited lower cell proliferation compared with control cells. In addition, KIF4A expression levels, as determined by immunohistochemistry, were compared with the expression of Ki-67, but no significant associations were observed in the patients with CRC. Therefore, KIF4A was found to be upregulated in patients with CRC and downregulation of KIF4A reduced cell proliferation in CRC cells. These results suggest that KIF4A may be a potential therapeutic target, which may improve the outcomes of patients with CRC.
驱动蛋白家族成员4A(KIF4A)是驱动蛋白相关蛋白的驱动蛋白4亚家族的成员,在细胞分裂中起重要作用。KIF4A的表达水平已在多种类型的癌症中进行了研究,包括宫颈癌、肺癌、口腔癌和乳腺癌,并且已确定与患者预后不良有关。然而,KIF4A在结直肠癌(CRC)中的作用及其表达仍有待阐明。因此,本研究调查了CRC患者中KIF4A的表达水平,并证明其在肿瘤组织中的水平高于非肿瘤组织。为了研究KIF4A的功能作用,在CRC细胞中敲低KIF4A,并评估细胞活力。与对照细胞相比,敲低KIF4A的CRC细胞表现出较低的细胞增殖。此外,通过免疫组织化学测定的KIF4A表达水平与Ki-67的表达进行了比较,但在CRC患者中未观察到显著关联。因此,发现CRC患者中KIF4A上调,KIF4A的下调降低了CRC细胞的增殖。这些结果表明,KIF4A可能是一个潜在的治疗靶点,这可能改善CRC患者的预后。